-$10.83
$6.45
bear -$10.83
base -$4.27
bull $6.45
margin of safety $1.50
market price* $22.49
Business condition attached to the margin of safety
Owner cash flow before interest running at roughly $100 million a year or better (operating income near $90-100 million annualized) for at least four straight quarters, and the June 2028 credit facility maturities refinanced or extended at rates near today's.
Fortrea is a global contract research organization: drug and device makers pay it to run clinical trials (Phase I to IV studies, clinical pharmacology units, trial management and monitoring). It was spun out of Labcorp on June 30, 2023 and sold its Patient Access and Endpoint businesses in 2024, so it now reports one segment. 2025 revenue was $2.72 billion (up 1.0%), spread across North America (47%), Europe (31%) and the rest of the world (21%). Contracted backlog was $7.7 billion at both year-ends 2024 and 2025, roughly 2.8 years of revenue, but the largest customer was 18.1% of 2025 revenue and the top ten were 57%. What the business actually earns. We measure cash generated for owners after removing swings in working capital (customer prepayments and collections), after treating stock compensation as a real cost, and after capital spending. Before interest, that came to about $1.22 per share in 2023, about -$1.07 in 2024 and about -$0.10 in 2025 (2022 was $2.84 but was a carve-out year inside Labcorp with a different cost base, so we do not use it). The 2023 to 2025 median, about -$0.10 per share or roughly -$9 million a year, is our starting anchor: over the years since the spin-off the business has generated close to nothing for owners before paying lenders. Reported operating cash flow looked far better ($263 million in 2024, $114 million in 2025) but was propped up by working-capital inflows of $384 million and $115 million, mostly customers paying in advance. Those are timing effects and we excluded them. The $798 million goodwill write-down in 2025 is non-cash and treated as a sunk acquisition cost; it also tells us the Clinical Development unit is worth far less than was paid for it. What is improving. SG&A fell 18.6% in 2025 to $456 million as transition-services and IT costs rolled off, and restructuring plans from Q4 2024 and Q4 2025 run through 2026. Operating income was a $75 million loss in 2025 before the impairment, but turned positive in the first half of 2026 (+$11.4 million; Q2 +$14.8 million versus -$3.4 million in Q1), the fourth straight quarter of improvement. Rebuilding first-half 2026 cash flow the same way, and removing a non-cash currency add-back and lease payments hidden in working capital, gives about $23 million for six months, or roughly $46 million a year before interest. Growth-path check: this business cash flow improved by about $86 million from 2024 to 2025; the base case assumes year one improves by about $55 million from 2025 (to $46 million), which is below the trailing improvement, so no unexplained acceleration is assumed. Offsetting this, direct costs rose to 81.5% of revenue from 80.2% (variable pay reintroduced, pass-through costs), and first-half 2026 revenue was 3.4% lower than a year earlier. Debt. Fortrea owes about $1.065 billion in face value: a term loan A of about $417 million (about $387.5 million due June 2028), a term loan B of $155 million due June 2030, and $494 million of 7.5% senior notes due 2030 (it retired $75.7 million in Q4 2025 with asset-sale proceeds). A $450 million revolver, undrawn, also matures June 2028. Cash interest was $109.6 million in 2024, $91.2 million in 2025 and $32.7 million in the first half of 2026. Covenants were loosened in February 2025 and the company reports compliance. Cash is $168.6 million; we treat about $100 million as needed to run the business, leaving about $69 million excess. The notes and term loan B cost more than 6% for about four years, adding roughly $30 million. Net debt used: about $1.027 billion, or $10.83 per share on 94.8 million diluted shares. A purported shareholder class action is also pending. Bear case (worth about -$10.83 per share). Named risks: the 2026 improvement fades back to the 2023-2025 median of roughly zero cash before interest, and the 2028 maturities (about $387.5 million term loan plus the revolver) cannot be refinanced on workable terms, with an 18%-of-revenue customer as a concentration. Business is worth $0, owes about $1.027 billion, difference about -$1.027 billion: on this path the company owes more than it is worth and the shares would have no value to a lender-first waterfall (we show the shortfall as a negative number, roughly $10.83 per share). Base case (about -$4.27 per share). Business cash flow steps up to about $46 million a year, the level already reached in the first half of 2026, and then drifts down 1.4% a year, matching the 2022-2025 revenue trend ($2,837 million to $2,723 million); we credit no margin expansion, new bookings or share gains, and management's margin targets are left out. Business worth about $622 million ($6.56 per share) less net debt of about $1.027 billion ($10.83) equals about -$404 million, or -$4.27 per share. Interest of roughly $65 million a year exceeds this cash flow, which is why equity comes out negative. Bull case (about $6.45 per share). The restructuring and cost reductions already under way carry operating income beyond the Q2 2026 run rate: business cash flow of $70 million in year one and $100 million from year two, held flat because backlog was steady at $7.7 billion and 2025 revenue grew. Business worth about $1,638 million ($17.28 per share) less net debt of about $1.027 billion ($10.83) equals about $612 million, or $6.45 per share. What we checked. The weak reading holds against the strongest counter-fact: even in a year with $798 million of write-downs stripped out, 2025 operating income was still negative, and the write-down itself is independent evidence of thin earning power. The optimistic reading rests on only two quarters of positive operating income, which is why the base case does not move above the first-half run rate. Things we could not fully reconcile: the 2022-2023 figures include carve-out costs and the Enabling Services businesses later sold, and first-half 2026 cash flow detail was rebuilt from tagged filing data rather than the full statement. What would make this wrong: a faster cost-out or pricing gains beyond the first half of 2026 (upside), or a customer loss or refinancing on worse terms (downside). At today's business cash flow, the shares are a leveraged bet on the turnaround continuing, and the debt, not the business, absorbs most of the value.